ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the Americ
March 01, 2017Eli Lilly and Company (NYSE: LLY) will highlight new Phase 3 data evaluating Taltz® (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 75th annual meeting of the American Academy of Dermatology (AAD
Pharma Sources Insight January 2025
